Vetoquinol (VETO) Q3 2026 TU earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 TU earnings summary
28 Oct, 2026Executive summary
Q3 sales reached €139.7m, up 10.4% reported and 9.6% at constant exchange rates, supported by Essentials growth and a favorable Q3 2025 base effect.
9M sales totaled €399.0m, up 3.9% reported and 5.4% at constant exchange rates; excluding product-line simplification, constant-currency growth was 6.6%.
Financial highlights
Q1 sales were €125.0m, down 4.3% reported and 0.3% at constant exchange rates; Q2 was €134.3m, up 5.7% and 7.2%, respectively.
Q3 sales were €139.7m, up 10.4% reported and 9.6% at constant exchange rates; favorable currency impact was €1m from the U.S. and Americas excluding the U.S.
9M reported sales growth was affected by a negative €6.1m currency impact and a €3.7m impact from product-line simplification.
Outlook and guidance
FY2026 annual sales release scheduled for January 14, 2027, after market close.
Latest events from Vetoquinol
- Net income rose 22% to €30.5M, driven by U.S. and Essentials growth, with improved margins.VETO
H1 2026 - Q1 2026 sales nearly flat at constant exchange rates, with strong U.S. rebound amid currency headwinds.VETO
Q1 2026 TU - Essentials growth and improved profitability drive strong 2025 results despite currency headwinds.VETO
H2 2025 - Essential Products drove growth to 64% of sales, offsetting currency and product range headwinds.VETO
Q4 2025 TU - Sales dipped 3.5% YTD, but Essential products grew to 64% of total sales.VETO
Q3 2025 TU - Essentials growth and higher margins offset sales decline, boosting profitability.VETO
H1 2025 - Sales grew 1.8% YTD, with essential products now 61% of total sales.VETO
Q3 2024 TU - Sales up 3.2%, profit margins down as US sales softened and investment rose.VETO
H1 2024 - Essentials drove 2.2% sales growth and profitability, offsetting U.S. decline.VETO
H2 2024